london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Endophthalmitis following sustained-release dexamethasone intravitreal implant- a case report

Poster Details

First Author: Y.Toklu TURKEY

Co Author(s):    M. Arıkan Yorgun   H.B. Çakmak   M. Mutlu   S. Uysal   N. Çağıl      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To report a rare case of a patient who presented with acute endophthalmitis following sustained-release dexamethasone intravitreal implant for branch retinal vein occlusion (BRVO).

Setting:

Acute endophtalmitis is a rare complication after sustained-release dexamethasone intravitreal implant

Methods:

A 58-year-old man admitted to our opthalmology department with the complaint of BRVO. Best-corrected visual acuity (BCVA) in the right eye was 0.2. He was treated with intravitreal Ozurdex® in the right eye. Two days after the injection, the patient presented with ocular pain and the visual acuity was hand movement. A diagnosis of endophthalmitis was made.

Results:

We performed emergent 23 gauge pars plana vitrectomy (PPV) and the implant was removed from the vitreous cavity using a retinal forceps. A combination of vancomycin 1.0 mg and amikacin 0.4 mg was injected intravitreally. However, because of the blurring in the vitreus one week after the procedure, phacoemulsification and a repeat PPV was performed. Five days after the last procedure the signs and symptoms of endophthalmitis were resolved. The final BCVA was 0,05 for the right eye. The results of both aqueous and vitreous cultures are negative.

Conclusions:

Our case demonstrated that endophthalmitis could develop after intravitreal implantation of Ozurdex. Surgical removal of the implant and immediate vitrectomy seems to be a useful treatment option in these cases.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy